We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+15.8%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$5.47B
AUM Growth
+$335M
Cap. Flow
+$416M
Cap. Flow %
7.6%
Top 10 Hldgs %
51.96%
Holding
75
New
18
Increased
7
Reduced
14
Closed
5

Top Buys

Rank Stock Value
1
NKTX icon
Nkarta
NKTX
+$165M
2
ASND icon
Ascendis Pharma A/S
ASND
+$143M
3
ITOS
iTeos Therapeutics
ITOS
+$119M
4
VXRT
Vaxart
VXRT
+$96.3M
5
MCRB icon
Seres Therapeutics
MCRB
+$79M

Top Sells

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$434M
2
TGTX icon
TG Therapeutics
TGTX
+$91.2M
3
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$84.2M
4
STOK icon
Stoke Therapeutics
STOK
+$26.7M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$25.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.86%
2 Miscellaneous 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNCE
51
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$18.3M 0.33%
1,858,474
– –
STSA
52
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$18.2M 0.33%
4,681,858
– –
MIST icon
53
Milestone Pharmaceuticals
MIST
$115M
$17.7M 0.32%
+2,418,798
New +$17.3M
SNDX icon
54
Syndax Pharmaceuticals
SNDX
$1.62B
$15.1M 0.28%
1,023,067
– –
TNGX icon
55
Tango Therapeutics
TNGX
$4.03B
$12.9M 0.24%
+1,250,000
New +$12.8M
RPTX
56
DELISTED
Repare Therapeutics
RPTX
$12.6M 0.23%
409,000
– –
FSDC
57
DELISTED
FS Development Corp. Class A Common Stock
FSDC
$11.2M 0.2%
+1,000,000
New +$10.7M
NAUT icon
58
Nautilus Biotechnolgy
NAUT
$113M
$10.8M 0.2%
+1,000,000
New +$10.7M
VSTM icon
59
Verastem
VSTM
$665M
$9.76M 0.18%
672,181
-88,590
-12% -$1.47M
SLDB icon
60
Solid Biosciences
SLDB
$897M
$9.28M 0.17%
304,744
– –
LYRA
61
DELISTED
LYRA THERAPEUTICS INC
LYRA
$9.25M 0.17%
16,317
– –
ARYBU
62
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
$7.7M 0.14%
700,000
– –
GRTX
63
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$7.46M 0.14%
825,118
– –
OBIO icon
64
Orchestra BioMed
OBIO
$363M
$6.88M 0.13%
+625,000
New +$7.02M
CLDX icon
65
Celldex Therapeutics
CLDX
$3.02B
$5.24M 0.1%
353,072
-796,928
-69% -$9.34M
ELVN icon
66
Enliven Therapeutics
ELVN
$3.91B
$5.08M 0.09%
62,435
-144,902
-70% -$13.1M
PASG icon
67
Passage Bio
PASG
$15.3M
$4.23M 0.08%
16,132
– –
XFOR icon
68
X4 Pharmaceuticals
XFOR
$359M
$3.79M 0.07%
18,650
– –
EPIX
69
DELISTED
ESSA Pharma
EPIX
$3.25M 0.06%
470,428
-378,872
-45% -$2.57M
OVID icon
70
Ovid Therapeutics
OVID
$529M
$1.64M 0.03%
285,000
– –
AVDL
71
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-3,126,131
Closed -$25.3M
INSM icon
72
Insmed
INSM
$26.2B
– –
-87,405
Closed -$2.41M
RNAC icon
73
Cartesian Therapeutics
RNAC
$239M
– –
-3,167
Closed -$270K
STOK icon
74
Stoke Therapeutics
STOK
$1.82B
– –
-1,119,963
Closed -$26.7M
MNTA
75
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-2,531,445
Closed -$84.2M
1 2
3

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, RA Capital Management held 75 positions worth $5.47B, up 6.5% from $5.13B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

RA Capital Management deployed $416M of net new capital in Q3 2020, opening 18 new positions and adding to 7 existing holdings. Its largest new stake was Nkarta: 5,605,129 shares worth $168M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Novavax, an estimated $434M trimmed.

  • RA Capital Management's largest Q3 2020 buy was Nkarta: 5,605,129 shares worth $168M.
  • RA Capital Management added most to Ascendis Pharma A/S in Q3 2020, an estimated $143M increase.
  • RA Capital Management's biggest Q3 2020 reduction was Novavax, cutting an estimated $434M.
  • RA Capital Management fully exited Momenta Pharmaceuticals, Inc. in Q3 2020, selling an estimated $84.2M.
  • RA Capital Management's ten largest holdings make up 52% of its $5.47B portfolio in Q3 2020.
  • RA Capital Management opened 18 new positions and closed 5 in Q3 2020.
  • RA Capital Management's portfolio value rose 6.5% quarter-over-quarter to $5.47B.

Based on RA Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.